bluebird bio, Inc. (BLUE) stock prices updated...

bluebird bio, Inc. stock price

bluebird bio, Inc. latest news:

  • 08/28/2017 09:41:09

    Biotech stocks surge on Gilead's Kite Pharma acquisition

    After news of Gilead Sciences Inc.'s about $11 billion acquisition of Kite Pharma Inc. , Juno Therapeutics Inc. shares surged 16.3%, Bluebird Bio Inc. shares surged 9.7% and Cellectis SA ADR shares surged 11.8% in extremely heavy midday trade Monday. The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T, which uses a patient's immune T-cells and re-engineers them to better fight cancer. Juno, Bluebird and Cellectis are other biotech companies working in CAR-T. BTIF analyst Dane Leone upgraded Juno on Monday, adding, "we continue to be skeptical of JUNO's current competitive positioning, but upgrade our ranking to Neutral from Sell, as there is not a near term catalyst to offset the positive tailwind for the entire CAR T space." Though there has been speculation about Celgene -- which owns about 10% of Juno's current shares outstanding -- acquiring Juno, "we would be surprised" by a full acquisition, Leone said, since "at this juncture with emerging overlap in Multiple Myeloma and third to market status in CD19 hematological malignancies, we struggle to find a rationale for Celgene wanting to fully own Juno." Kite Pharma shares surged 28% in extremely heavy morning trade. Shares have surged 144% over the last three months, compared with a 1% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit for more information on this news.

  • 08/02/2017 14:39:43

    BRIEF-Bluebird Bio Q2 net loss per share $1.73

    Bluebird Bio Inc(BLUE). * Bluebird Bio(BLUE) reports second quarter 2017 financial results and recent operational progress. * Q2 revenue $16.7 million versus $1.6 million. * Q2 revenue view $5.2 million -- Thomson Reuters I/B/E/S. * Bluebird Bio (BLUE) sees that cash, cash equivalents & marketable securities of $1.2 billion as of June 30, 2017 will be sufficient to fund current operations into 2020.

  • 06/27/2017 09:10:35

    Bluebird Bio Gears Up for $350 Million Offering

  • 06/26/2017 14:31:30

    BRIEF-Bluebird Bio announces proposed public offering of common stock

    * Bluebird Bio announces proposed public offering of common stock

  • More trends:

    Blueknight Energy Partners L.P., L.L.C.BKEP | Blueknight Energy Partners L.P., L.L.C.BKEPP | Blueprint Medicines CorporationBPMC | BNC BancorpBNCN | Bob Evans Farms, Inc.BOBE | BofI Holding, Inc.BOFI | Boingo Wireless, Inc.WIFI | Bojangles'', Inc.BOJA | BOK Financial CorporationBOKF | Bona Film Group LimitedBONA |